Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II neoadjuvant befotertinib + vorolanib in resectable stage II-IIIB EGFR-mutant NSCLC
ChiCTR2400093236Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of befotertinib and vorolanib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: maximum tolerated dose, recommended phase II dose and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
befotertinibvorolanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400093236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093236.